Poor results for CurVac

The cheif executive of CureVac said Thursday that interim results from late-stage testing of its coronavirus shot are sobering, but the German company aims to finish a final analysis within weeks that will determine whether it will still seek regulatory approval. CureVac announced late Wednesday that the vaccine had shown an efficacy of 47% against Covid-19 of any severity, according to a partial review of data from its trial involving 40,000 participants in Latin America and Europe. This is below the WHO threshold of 50%. The company said more than two dozen variants of the coronavirus were found in its trials across 10 countries, a fact that may have affected the outcome.

Categories: News